Intriguingly, if HTICS− patients can be classified as a subgroup of HER2+:ERα− BC (see next section), there is a possibility that other clinical parameters or signatures could further separate group 1b and help identify novel treatments for these patients. This evidence concerns the gene ERBB2 and breast cancer.